Genomma Lab stock costs EUR 0.64 with MXN 12.8 billion market cap

Published on 10/12/2026 at 15:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

On October 12, 2026, Genomma Lab stock was at EUR 0.64. Its MXN 12.8 billion value pairs with a 7.9 P/E ratio.

Key points in brief

Genomma Lab stock was at EUR 0.64 at Lang & Schwarz on October 12, 2026 at 3:25 p.m. CEST.
Market capitalization was MXN 12.8 billion as of October 9, 2026, with a P/E ratio of 7.9.
Second-quarter 2026 revenue reached MXN 4.397 billion and net income was MXN 374.5 million.
Third-quarter results are scheduled for October 21, 2026, after the BMV close.

Genomma Lab, MX01LA010006, Illustration mit AI erstellt.

Genomma Lab stock (ISIN MX01LA010006) was at EUR 0.64 at Lang & Schwarz on October 12, 2026 at 3:25 p.m. CEST. The quote places the Mexico-listed consumer-health company alongside a market capitalization of MXN 12.8 billion and a P/E ratio of 7.9.

Price sits below the annual high

The Lang & Schwarz quote is the euro price for German investors, while the primary BMV listing provides the local-currency context. The BMV quote stood at MXN 13.06 on October 9, 2026, with a 52-week range of MXN 12.22 to MXN 19.48.

Trading volume in the BMV quote was 4,311,051 shares, compared with an average volume of 3,410,216 shares. The annual range places the local-market quotation 37.88 percent below its high, calculated from MXN 13.06 and MXN 19.48.

Revenue and earnings set the baseline

According to Investing.com, Genomma Lab reported revenue of MXN 4.397 billion and net income of MXN 374.5 million in the second quarter of 2026. Revenue increased from MXN 4.191 billion in the first quarter, while net income declined from MXN 494.6 million.

The quarter therefore combined sequential revenue growth of 4.93 percent with a 24.30 percent decline in net income. The company operates across pharmaceutical and personal-care products, giving the upcoming quarterly release importance for both sales momentum and profitability.

Comparison with peers

Genomma Lab: , P/E 7.9, market capitalization MXN 12.8 billion

Kimberly-Clark de Mexico (BMV, MXN): plus 0.4 percent, P/E 14.3, market capitalization MXN 113.7 billion

Grupo Bimbo (BMV, MXN): plus 0.2 percent, P/E 20.5, market capitalization MXN 241.5 billion

Results date is October 21

As Yahoo Finance reports from the company release dated October 1, 2026, Genomma Lab will report third-quarter 2026 results on October 21, 2026, after the Mexican Stock Exchange close. The conference call is scheduled for October 22, 2026, at 11:00 a.m. Mexico City time.

For investors, the key comparison is between the 4.93 percent sequential revenue increase and the 24.30 percent sequential net-income decline. That split makes the next report a test of whether sales growth can translate into earnings momentum.

Genomma Lab market snapshot

Genomma Lab was at EUR 0.64 at Lang & Schwarz on October 12, 2026 at 3:25 p.m. CEST. Its market capitalization was MXN 12.8 billion as of October 9, 2026, and its BMV 52-week range was MXN 12.22 to MXN 19.48.

The further course of trading is shown by the continuously updated real-time quote of Genomma Lab stock.